3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Ovarian Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Uterine Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Neoadjuvant Therapy
1
Lung Neoplasms
1
Kenny-Caffey syndrome, Type 1
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
270
Bevacizumab
260
Fluorouracil
249
Irinotecan
240
Leucovorin
218
Capecitabine
196
Cetuximab
161
Colonoscopy
74
Folfox protocol
70
Panitumumab
64
regorafenib
62
Drug Therapy
52
Radiotherapy
50
HMPL-013
50
Blood Specimen Collection
45
trifluridine tipiracil drug combination
43
pembrolizumab
41
Surveys and Questionnaires
35
Standard of Care
35
Nivolumab
34
Neoadjuvant Therapy
34
Surgical Procedures, Operative
33
Magnetic Resonance Spectroscopy
31
IFL protocol
27
Trifluridine
26
Interviews as Topic
26
Celecoxib
26
XELOX
25
Early Intervention, Educational
24
Specimen Handling
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Colorectal Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled